Assessment of solid cancer treatment feasibility in older patients: A prospective cohort study

Oncologist

Volumn 19, Issue 3, 2014, Pages 275-282

  Laurent, Marie ^a,b   Paillaud, Elena ^a,b   Tournigand, Christophe ^c   Caillet, Philippe ^a,b   Thuaut, Aurélie Le ^a,c   Lagrange, Jean Léon ^c   Beauchet, Olivier ^d   Vincent, Hélène ^e   Carvahlo Verlinde, Muriel ^c   Culine, Stéphane ^f   Bastuji Garin, Sylvie ^a,c   Canouï Poitrine, Florence ^a,c  

^a UNIVERSITÉ PARIS EST CRÉTEIL   (France)

^b Département de Médecine Interne et Gériatrie Unité de Coordination d'Onco Gériatrie UCOG Sud Val de Marne   (France)

^c HENRI MONDOR HOSPITAL   (France)

^d ANGERS UNIVERSITY HOSPITAL   (France)

^e HÔPITAL PAUL BROUSSE   (France)

^f SAINT LOUIS HOSPITAL   (France)

Author keywords

Cancer; Chemotherapy; Elderly; Feasibility studies; Treatment

Indexed keywords

C REACTIVE PROTEIN; SERUM ALBUMIN;

AGED; ARTICLE; BILIARY TRACT CANCER; BLADDER CANCER; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER THERAPY; COHORT ANALYSIS; COLORECTAL CANCER; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; FEASIBILITY STUDY; FEMALE; GERIATRIC PATIENT; HEAD AND NECK CANCER; HUMAN; KIDNEY CANCER; LIVER CANCER; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; OVARY CANCER; PANCREAS CANCER; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CANCER; SKIN CANCER; SOLID TUMOR; STOMACH CANCER; URINARY TRACT CANCER; UTERUS CANCER; VERY ELDERLY; AGE; GERIATRIC ASSESSMENT; INFORMATION PROCESSING; MULTIMODALITY CANCER THERAPY; NEOPLASMS; TREATMENT OUTCOME;

AGE FACTORS; AGED; AGED, 80 AND OVER; COHORT STUDIES; COMBINED MODALITY THERAPY; DATA COLLECTION; FEASIBILITY STUDIES; FEMALE; GERIATRIC ASSESSMENT; HUMANS; MALE; NEOPLASMS; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84896458248     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2013-0351     Document Type: Article

References (57)

1. Smith BD, Smith GL, Hurria A et al. Future of cancer incidence in the United States: Burdens upon an aging, changing nation. J Clin Oncol 2009; 27: 2758-2765.
2. Jemal A, Siegel R, Xu J et al. Cancer statistics, 2010. CA Cancer J Clin 2010; 60: 277-300.
3. Jonker DJ, Spithoff K, Maroun J. Adjuvant systemic chemotherapy for stage II and III colon cancer after complete resection: An updated practice guideline. Clin Oncol (R Coll Radiol) 2011; 23: 314-322.
4. Goldberg RM, Tabah-Fisch I, Bleiberg H et al. Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patientswith colorectal cancer. J Clin Oncol 2006; 24: 4085-4091.
5. Muss HB, Berry DA, Cirrincione C et al. Toxicity of older and younger patients treated with adjuvant chemotherapy for node-positive breast cancer: The Cancer and Leukemia Group B experience. J Clin Oncol 2007; 25: 3699-3704.
6. Pavlidis TE, Marakis G, Ballas K et al. Safety of bowel resection for colorectal surgical emergency in the elderly. Colorectal Dis 2006; 8: 657-662.
7. Spivak H, Maele DV, Friedman I et al. Colorectal surgery in octogenarians. J Am Coll Surg 1996; 183: 46-50.
8. Folprecht G, Seymour MT, Saltz L et al. Irinotecan/fluorouracil combination in first-line therapy of older and younger patients with metastatic colorectal cancer: Combined analysis of 2, 691 patients in randomized controlled trials. J Clin Oncol 2008; 26: 1443-1451.
9. Cassidy J, Saltz LB, Giantonio BJ et al. Effect of bevacizumab in older patients with metastatic colorectal cancer: Pooled analysis of four randomized studies. J Cancer Res Clin Oncol 2010; 136: 737-743.
10. Van Spall HG, Toren A, Kiss A et al. Eligibility criteria of randomized controlled trials published in high-impact general medical journals: A systematic sampling review. JAMA 2007; 297: 1233-1240.
11. Köhne CH, Folprecht G, Goldberg RM et al. Chemotherapy in elderly patients with colorectal cancer. The Oncologist 2008; 13: 390-402.
12. Aparicio T, Navazesh A, Boutron I et al. Half of elderly patients routinely treated for colorectal cancer receive a sub-standard treatment. Crit Rev Oncol Hematol 2009; 71: 249-257.
13. Hurria A, Togawa K, Mohile SG et al. Predicting chemotherapy toxicity in older adults with cancer: A prospective multicenter study. J Clin Oncol 2011; 29: 3457-3465.
14. Audisio RA, Bozzetti F, Gennari R et al. The surgical management of elderly cancer patients; recommendations of the SIOG surgical task force. Eur J Cancer 2004; 40: 926-938.
15. Carreca I, Balducci L, Extermann M. Cancer in the older person. Cancer Treat Rev 2005; 31: 380-402.
16. Soubeyran P, Henriques de Figueiredo B, Soubeyran I et al. Therapeutic strategies in elderly and very elderly patients. Best Pract Res Clin Haematol 2012; 25: 91-100.
17. Townsley C, Pond GR, Peloza B et al. Analysis of treatment practices for elderly cancer patients in Ontario, Canada. J Clin Oncol 2005; 23: 3802-3810.
18. Mitry E, Rollot F, JoosteVet al. Improvementin survival of metastatic colorectal cancer: Are the benefits of clinical trials reproduced in populationbased studies? Eur J Cancer 2013; 49: 2919-2925.
19. Dobie SA, Baldwin LM, Dominitz JA et al. Completion of therapy by Medicare patients with stage III colon cancer. J Natl Cancer Inst 2006; 98: 610-619.
20. Ahmed S, Ahmad I, Zhu T et al. Early discontinuation but not the timing of adjuvant therapy affects survival of patients with high-risk colorectal cancer: A population-based study. Dis Colon Rectum 2010; 53: 1432-1438.
21. Margalit DN, Mamon HJ, Ancukiewicz M et al. Tolerability of combined modality therapy for rectal cancer in elderly patients aged 75 years and older. Int J Radiat Oncol Biol Phys 2011; 81: e735-e741.
22. Aaldriks AA, Maartense E, le Cessie S et al. Predictive value of geriatric assessment for patients older than70 years, treatedwith chemotherapy. Crit Rev Oncol Hematol 2011; 79: 205-212.
23. Neugut AI, Matasar M, Wang X et al. Duration of adjuvant chemotherapy for colon cancer and survival among the elderly. J Clin Oncol 2006; 24: 2368-2375.
24. Aparicio T, Jouve JL, Teillet L et al. Geriatric factors predict chemotherapy feasibility: Ancillary results of FFCD 2001-02 phase III study in first-line chemotherapy for metastatic colorectal cancer in elderly patients. J Clin Oncol 2013; 31: 1464-1470.
25. von Elm E, Altman DG, Egger M et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: Guidelines for reporting observational studies. Lancet 2007; 370: 1453-1457.
26. Agence Nationale d'Accréditation et d'Evaluation en Santé. Diagnostic de l'insuffisance r énale chronique chez l'adulte. Synthèse des recommandations, Septembre 2002. Available at http://www. has-sante. fr/portail/upload/docs/application/pdf/irc_chez_ladulte_2002_-_synth_350se. pdf. Accessed September 15, 2013.
27. Caillet P, Canoui-Poitrine F, Vouriot J et al. Comprehensive geriatric assessment in the decisionmaking process in elderly patients with cancer: ELCAPA study. J Clin Oncol 2011; 29: 3636-3642.
28. Extermann M, Hurria A. Comprehensive geriatric assessment for older patients with cancer. JClin Oncol 2007; 25: 1824-1831.
29. ExtermannM, AaproM, BernabeiRet al. Useof comprehensive geriatric assessment in older cancer patients: Recommendations from the task force on CGA of the International Society of Geriatric Oncology (SIOG). Crit Rev Oncol Hematol 2005; 55: 241-252.
30. Katz S, Ford AB, MoskowitzRWet al. Studies of illness in the aged. The index of ADL: A standardized measure of biological and psychosocial function. JAMA 1963; 185: 914-919.
31. Orr ST, Aisner J. Performance status assessment among oncology patients: A review. Cancer Treat Rep 1986; 70: 1423-1429.
32. Podsiadlo D, Richardson S. The timed "Up & Go": A test of basic functional mobility for frail elderly persons. J AmGeriatr Soc 1991; 39: 142-148.
33. Guigoz Y, Vellas B. The Mini Nutritional Assessment (MNA) for grading the nutritional state of elderly patients: Presentation of theMNA, history and validation. Nestle Nutr Workshop Ser Clin Perform Programme 1999; 1: 3-11; discussion 11-12.
34. Folstein MF, Folstein SE, McHugh PR. "Minimental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189-198.
35. Cl ément JP, Darthout N, Nubukpo P. Life events, personality and dementia. [in French]. Psychol Neuropsychiatr Vieil 2003; 1: 129-138.
36. Linn BS, Linn MW, Gurel L. Cumulative illness rating scale. J Am Geriatr Soc 1968; 16: 622-626.
37. Common Terminology Criteria for Adverse Events (CTCAE) Version 4. 0. Available at http://www. eortc. be/services/doc/ctc/CTCAE_4. 03_2010-06-14_QuickReference_5x7. pdf. AccessedMay2013.
38. Audisio RA, Pope D, Ramesh HS et al. Shall we operate? Preoperative assessment in elderly cancer patients (PACE) can help. A SIOG surgical task force prospective study. Crit Rev Oncol Hematol 2008; 65: 156-163.
39. Des Guetz GUB, Morere JF, Perret G et al. Duration of adjuvant chemotherapy for patients with non-metastatic colorectal cancer. Cochrane Database Syst Rev 2010: CD007046.
40. Best LSP, Baughan C, Buchanan R et al. Palliative chemotherapy for advanced or metastatic colorectal cancer. Cochrane DatabaseSystRev 2000: CD001545.
41. Haute Autorit é de Santé. Available at http://www. has-sante. fr/portail/jcms/c_5073/professionelsde-sante?cid5c_5073. Accessed September 15, 2013.
42. Freyer G, Geay JF, Touzet S et al. Comprehensive geriatric assessment predicts tolerance to chemotherapy and survival in elderly patients with advanced ovarian carcinoma: A GINECO study. Ann Oncol 2005; 16: 1795-1800.
43. Marinello R, Marenco D, Roglia D et al. Predictors of treatment failures during chemotherapy: A prospective study on 110 older cancer patients. Arch Gerontol Geriatr 2009; 48: 222-226.
44. Soubeyran P, Fonck M, Blanc-Bisson C et al. Predictors of early death risk in older patients treated with first-line chemotherapy for cancer. J Clin Oncol 2012; 30: 1829-1834.
45. Chrischilles EA, Link BK, Scott SD et al. Factors associated with early termination of CHOP therapy and the impact on survival among patients with chemosensitive intermediate-grade non-Hodgkin's lymphoma. Cancer Contr 2003; 10: 396-403.
46. Fairfield KM, Murray K, Lucas FL et al. Completion of adjuvant chemotherapy and use of health services for older women with epithelial ovarian cancer. J Clin Oncol 2011; 29: 3921-3926.
47. ExtermannM, Boler I, ReichRRet al. Predicting the risk of chemotherapy toxicity in older patients: The Chemotherapy Risk Assessment Scale for High-Age Patients (CRASH) score. Cancer 2012; 118: 3377-3386.
48. André T, Boni C, Navarro M et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 2009; 27: 3109-3116.
49. O'Connor TL, Edge S, Kossoff EB et al. Factors affecting the delivery of adjuvant/neoadjuvant chemotherapy in older women with breast cancer. J Geriatr Oncol 2012; 3: 320-328.
50. Gronlund B, Høgdall C, Hansen HH et al. Performance status rather than age is the key prognostic factor in second-line treatmentofelderly patients with epithelial ovarian carcinoma. Cancer 2002; 94: 1961-1967.
51. Fiorica F, Cartei F, Carau B et al. Adjuvant radiotherapy on older and oldest elderly rectal cancer patients. Arch Gerontol Geriatr 2009; 49: 54-59.
52. Janssen-Heijnen ML, Maas HA, van de Schans SA et al. Chemotherapy in elderly small-cell lung cancer patients: Yes we can, but should we do it? Ann Oncol 2011; 22: 821-826.
53. Lund JL, Sturmer T, Harlan LC et al. Identifying specific chemotherapeutic agents in Medicare data: A validation study. Med Care 2013; 51: e27-e34.
54. Paulsen T, Kjaerheim K, Kaern J et al. Improved short-term survival for advanced ovarian, tubal, and peritoneal cancer patients operated at teaching hospitals. Int J Gynecol Cancer 2006; 16(suppl 1): 11-17.
55. Carola E. Predictive factors for chemotherapy feasibility in elderly patients with solid tumor: Results of GERCOR old prospective multicenter study. Presentation at: American Society of Clinical Oncology annual meeting; May 31-June 4, 2013; Chicago, IL.
56. Groupe Cooperateur Multidisciplinaire en Oncologie. Combination chemotherapy in treating older patients with metastatic breast, colorectal, or ovarian cancer that cannot be removed by surgery [identifier NCT00664911]. Available at http://clinicaltrials. gov/ct2/show/NCT00664911?term5 NCT00664911&rank51. Accessed September 15, 2013.
57. Decoster L, Kenis C, Van Puyvelde K et al. The influence of clinical assessment (including age) and geriatric assessment on treatment decisions in older patients with cancer. J Geriatr Oncol 2013; 4: 235-241.